查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2008771

治疗性疫苗市场报告：按类型、疾病、技术、分销管道和地区划分（2026-2034 年）

Therapeutic Vaccines Market Report by Type, Disease Type, Technology, Distribution Channel, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 148 Pages | 商品交期: 2-3个工作天内

价格

2025年，全球治疗性疫苗市场规模达374亿美元。展望未来，IMARC集团预测，到2034年，该市场规模将达到785亿美元，2026年至2034年的复合年增长率（CAGR）为8.32%。北美是推动市场成长的主要地区，这主要得益于治疗选择有限的疾病日益普遍以及技术的进步。微创手术（MIS）的日益普及以及製药公司、研究机构和学术界之间合作的不断加强，都是提升市场份额的关键因素。

治疗性疫苗（也称为免疫疗法疫苗）是一种旨在刺激患者自体免疫系统对抗特定疾病的医疗介入。与化疗等传统治疗方法相比，治疗性疫苗的副作用较少。它们能在不损伤健康细胞的情况下刺激免疫系统，并有助于降低初始治疗后疾病復发的可能性。此外，治疗性疫苗还可以与其他治疗方法（如化疗和标靶治疗）合併使用，产生协同效应。在治疗人类免疫力缺乏病毒（HIV）和B型肝炎等慢性感染疾病方面，治疗性疫苗可透过增强免疫反应来抑制病毒量并延缓疾病进展。

某些癌症和罕见疾病等治疗手段有限的疾病日益普遍，推动了对疫苗等创新疗法的需求。此外，人口老化加剧了对各种慢性疾病的易感性，也增加了对治疗性疫苗等新型治疗方法的需求。世界各国政府都在为免疫疗法和疫苗领域的研发提供支持性政策、津贴和资金。此外，人们越来越倾向于选择非侵入性或微创治疗方法，也推动了对治疗性疫苗的需求。製药公司、研究机构和学术界之间的合作也正在加速治疗性疫苗的研发和商业化。

治疗性疫苗市场趋势：

癌症负担加重

传统的治疗方法，例如化疗和放射线治疗，往往毒性较大且长期疗效有限，因此，日益严重的全球癌症负担成为推动市场扩张的主要动力。根据印度医学研究理事会（ICMR）预测，到2025年，癌症患者人数将比2020年增加12.8%。随着生活方式的改变、人口老化和环境因素导致癌症病例增加，人们对副作用更少、疗效更持久的创新治疗方法的需求日益增长。治疗性疫苗旨在激活人体免疫系统，识别并标靶化癌细胞，正逐渐成为一种很有前景的选择。它们能够补充现有治疗方法并预防復发，这是其主要吸引力所在。随着全球癌症发生率的持续上升，医疗机构和研究机构正将疫苗治疗方法列为优先事项，加速了市场投资和应用。

人们对免疫疗法的关注度日益提高。

免疫疗法作为慢性病和危及生命的疾病的一线治疗方案，其日益增长的关注度正在推动市场发展。与直接针对病变细胞的传统治疗方法不同，免疫疗法利用患者自身的免疫系统来识别和靶向有害病原体，从而提供更持久的疗效和更低的毒性。 2025年9月，由BioNTech及其合作伙伴百时美施贵宝（BMY.N）共同研发的尖端癌症免疫疗法在转移性小细胞肺癌的中期临床试验中显示出令人鼓舞的肿瘤缩小效果。这项II期临床试验的结果显示，在接受BNT327（普米他米）治疗的38名受试者中，76.3%的受试者肿瘤缩小，该药物符合中期分析的标准。治疗性疫苗作为免疫刺激剂，针对癌细胞、病毒和其他病原体。免疫疗法在肿瘤学和感染疾病治疗领域的成功应用，使其信誉度不断提升，从而推动了对基于疫苗的免疫疗法的需求。

对个人化医疗的需求日益增长

患者和临床医生对针对个别基因和分子特征的标靶治疗的需求日益增长，推动了个人化医疗市场的发展。根据IMARC集团预测，全球精准医疗市场规模预计在2024年达到821亿美元。与传统的、千篇一律的治疗方法不同，治疗性疫苗可以根据特定的肿瘤抗原或免疫系统突变进行定制，从而改善治疗效果并最大限度地减少副作用。基因组学和生物标记发现的进步使研究人员能够设计出针对患者独特生物学特征的疫苗，为更精准、更有效的治疗方法铺平了道路。这种向个人化的转变不仅提高了病患满意度和存活率，也推动了疫苗研发投入的增加。

治疗性疫苗市场的主要成长要素：

技术进步

去氧核糖核酸(DNA) 和信使核糖核酸 (mRNA) 疫苗技术的进步，透过加快研发速度、提高疗效和拓展应用范围，为市场带来了良好的前景。这些平台能够精确编码抗原，刺激针对特定疾病（包括癌症和慢性感染疾病）的强效标靶免疫反应。与传统疫苗不同，DNA 和 mRNA 技术可以快速设计、製造和大规模生产，从而降低成本并缩短研发时间。它们的柔软性也支持个人化治疗的定制，与精准医疗的发展趋势高度契合。随着创新不断推进，DNA 和 mRNA 疫苗有望开启新的治疗可能性，并推动市场强劲成长和广泛应用。

扩大生物技术公司与学术机构之间的合作

生物技术公司与学术机构之间日益增多的伙伴关係，透过将前沿科学研究与商业开发专长相结合，正对市场产生积极影响。学术机构通常主导早期发现，例如新型抗原和免疫机制的核准，而生物技术公司则提供临床试验、监管审批和商业化所需的资源和基础设施。此类合作有助于加速创新，缩短产品上市时间，并提高疫苗开发等高度复杂和高风险领域的成功率。此外，这些合作也促进了知识共用、先进技术的获取以及专业人才的培养。透过整合智力资源和资金，生物技术公司与学术机构的伙伴关係正在建立强大的治疗性疫苗候选产品线，显着推动市场成长。

政府加大对疫苗研发的投入

政府加大对疫苗研发的投入是推动市场成长的主要动力。这是因为公共部门的支持为推动创新研发和临床试验提供了必要的资金基础。已开发经济体和新兴经济体的政府机构正在投入大量资源，以加强医疗卫生基础设施建设，促进生物技术创新，并加速慢性病和感染疾病先进治疗方法的早期应用。此类资金投入降低了私人公司的风险，促进了合作，并加速了研究成果向市场化产品的转换。此外，政府主导的措施也有助于制定监管奖励，改善尖端平台的使用，并促进国际伙伴关係。这种积极的财政和政策支持确保了持续创新和广泛应用，最终使治疗性疫苗成为现代医疗保健策略的重要组成部分。

目录

第一章：序言

第二章：调查方法

  • 调查目的
  • 相关利益者
  • 数据来源
    • 主要讯息
    • 二手资讯
  • 市场估值
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章执行摘要

第四章：引言

第五章：全球治疗性疫苗市场

  • 市场概览
  • 市场表现
  • 新冠疫情的影响
  • 市场预测

第六章 市场区隔：依类型

  • 抗原疫苗
  • 树突细胞疫苗
  • DNA疫苗
  • 癌细胞疫苗

第七章 市场区隔：依疾病类型划分

  • 自体免疫疾病疫苗
  • 成瘾疫苗
  • 神经系统疾病疫苗
  • 感染疾病疫苗
  • 其他的

第八章 市场区隔：依技术划分

  • 自体疫苗
  • 同型疫苗

第九章 市场区隔：依分销通路划分

  • 医院药房
  • 零售药房
  • 网路药房

第十章 市场区隔：依地区划分

  • 北美洲
    • 我们
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第十一章 SWOT 分析

第十二章：价值链分析

第十三章：波特五力分析

第十四章：价格分析

第十五章 竞争格局

  • 市场结构
  • 主要企业
  • 主要企业简介
    • Agenus Inc.
    • Bavarian Nordic
    • CEL-SCI Corporation
    • Dendreon Pharmaceuticals LLC.
    • Emergent BioSolutions
    • GeoVax
    • GSK plc
    • Merck & Co., Inc.
    • Novavax
    • Nykode Therapeutics ASA
    • Pfizer Inc.
    • Phio Pharmaceuticals
    • Sanofi SA
Product Code: SR112026A6496

The global therapeutic vaccines market size reached USD 37.4 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 78.5 Billion by 2034, exhibiting a growth rate (CAGR) of 8.32% during 2026-2034. North America dominates the market, driven by rising prevalence of diseases with limited treatment options and technological advancements. Increasing preferences for minimally invasive surgeries (MIS) and the growing partnerships between pharmaceutical companies, research institutions, and academia are some of the major factors propelling the market share.

Therapeutic vaccines, also known as treatment vaccines or immunotherapeutic vaccines, are a type of medical intervention designed to stimulate the immune system of patients to target and combat specific diseases. They have fewer side effects compared to traditional treatments like chemotherapy. They stimulate the immune system without causing extensive damage to healthy cells. They help reduce the likelihood of disease recurrence after initial treatment. They can be combined with other treatments, such as chemotherapy or targeted therapies, to create a synergistic effect. They aid in managing chronic infections like human immunodeficiency viruses (HIV) and hepatitis B by enhancing the immune response to control the viral load and minimize disease progression.

The rising prevalence of diseases with limited treatment options, such as certain types of cancers and rare disorders, is catalyzing the demand for innovative therapeutic approaches like vaccines. Additionally, the increasing aging population aging population, which is highly susceptible to various chronic ailments is driving the need for novel treatment modalities like therapeutic vaccines. Apart from this, governments of various countries are offering supportive policies, grants, and funding for research and development (R&D) in the field of immunotherapy and vaccines. Furthermore, the rising preferences of individuals for non-invasive or minimally invasive treatment options are driving the demand for therapeutic vaccines. Moreover, partnerships between pharmaceutical companies, research institutions, and academia are accelerating the development and commercialization of therapeutic vaccines.

THERAPEUTIC VACCINES MARKET TRENDS:

Rising burden of cancer

The growing global burden of cancer is a key factor fueling the expansion of the market, as conventional treatments like chemotherapy and radiation often come with high toxicity and limited long-term effectiveness. According to the Indian Council of Medical Research, a forecasted 12.8% increase in cancer cases is expected by 2025 relative to 2020. With cancer cases rising due to lifestyle changes, aging population, and environmental factors, there is a growing demand for innovative solutions that provide durable responses with fewer side effects. Therapeutic vaccines, crafted to activate the body's immune system to identify and target tumor cells, are emerging as a promising option. Their ability to complement existing therapies and potentially prevent relapse makes them highly attractive. As cancer incidence continues to rise worldwide, healthcare providers and research organizations are prioritizing vaccine-based therapies, thereby accelerating investments and adoption across the market.

Growing focus on immunotherapy

Rising focus on immunotherapy as a frontline approach to treating chronic and life-threatening diseases is driving momentum in the market. Unlike conventional treatments that directly target diseased cells, immunotherapy leverages the patient's immune system to identify and target harmful agents, offering longer-lasting effects and lesser toxicity. In September 2025, a cutting-edge cancer immunotherapy from BioNTech and partner Bristol Myers Squibb (BMY.N) showed promising tumor reduction in a mid-stage trial for small cell lung cancer that was beginning to metastasize. A Phase II trial indicated that 76.3% of the 38 participants receiving the drug BNT327, or pumitamig, who met criteria for an interim analysis experienced a decrease in their tumors. Therapeutic vaccines act as immune stimulants to target cancer cells, viruses, or other disease-causing agents. As immunotherapy is gaining credibility through successful outcomes in oncology and infectious disease management, the demand for vaccine-based immunotherapies is rising.

Increasing personalized medicine demand

Rising demand for personalized medicine is positively influencing the market, as patients and clinicians are seeking targeted treatments tailored to individual genetic and molecular profiles. As per the IMARC Group, the global precision medicine market size reached USD 82.1 Billion in 2024. Unlike traditional one-size-fits-all approaches, therapeutic vaccines can be developed to match specific tumor antigens or immune system variations, enhancing treatment outcomes and minimizing adverse effects. Advancements in genomics and biomarker discovery are enabling researchers to design vaccines that align with patients' unique biological characteristics, paving the way for more precise and effective therapies. This shift towards personalization is not only improving patient satisfaction and survival rates but also attracting higher investments in vaccine research and development (R&D) activities.

KEY GROWTH DRIVERS OF THERAPEUTIC VACCINES MARKET:

Advancements in technology

Advancements in deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) vaccine technology are offering a favorable market outlook by enabling faster development, higher efficacy, and broader application potential. These platforms allow precise encoding of antigens that stimulate strong and targeted immune responses against specific diseases, including cancer and chronic infections. Unlike traditional vaccines, DNA and mRNA technologies can be quickly designed, manufactured, and scaled, reducing both cost and development timelines. Their flexibility also supports customization for personalized therapies, aligning well with the shift towards precision medicine. As innovation continues, DNA and mRNA vaccines are expected to unlock new treatment possibilities, driving robust growth and adoption in the market.

Expanding collaborations between biotech firms and academia

Rising partnerships between biotech firms and academic institutions are positively influencing the market, bridging cutting-edge scientific research with commercial development expertise. Academic institutions often drive early-stage discoveries, such as identifying novel antigens or immune mechanisms, while biotech companies bring the resources and infrastructure needed for clinical trials, regulatory approval, and commercialization. These collaborations aid in accelerating innovations, reducing time-to-market, and enhancing the chances of success in a highly complex and high-risk field like vaccine development. Furthermore, alliances promote knowledge sharing, access to advanced technologies, and training of skilled professionals. By pooling intellectual and financial resources, biotech-academia partnerships are creating a strong pipeline of therapeutic vaccine candidates, significantly advancing the market growth trajectory.

Rising government funding for vaccine development

Increasing government funding for vaccine development is a major driver of the market growth, as public sector support provides the financial backbone needed to advance innovative research and clinical trials. Government agencies across developed and emerging economies are allocating significant resources to strengthen healthcare infrastructure, promote biotechnology innovation, and accelerate the availability of advanced therapies for chronic and infectious diseases. Such funding reduces the risk for private companies, encouraging collaboration and faster translation of discoveries into market-ready products. Moreover, government-backed initiatives help create regulatory incentives, improve access to cutting-edge platforms, and foster international partnerships. This proactive financial and policy support ensures sustained innovations and widespread adoption, ultimately positioning therapeutic vaccines as a vital component of modern healthcare strategies.

THERAPEUTIC VACCINES INDUSTRY SEGMENTATION:

Breakup by Type:

  • Antigen Vaccines
  • Dendritic Cell Vaccine
  • DNA Vaccine
  • Tumor Cell Vaccines

Tumor cell vaccines hold the largest market share

Breakup by Disease Type:

  • Autoimmune Disease Vaccines
  • Addiction Vaccine
  • Neurological Disease Vaccine
  • Infectious Disease Vaccine
  • Others

Autoimmune disease vaccines represent the largest market segment

Breakup by Technology:

  • Autologous Vaccines
  • Allogeneic Vaccine

Autologous vaccines account for the majority of the market share

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Hospital pharmacies operate within healthcare facilities, which ensures direct access to patients undergoing treatments. They facilitate immediate availability, expert guidance, and seamless integration with medical care and aid in dispensing and administering therapeutic vaccines, especially for critical conditions requiring close medical supervision.

Retail pharmacies are widespread and easily accessible to the general population. They offer convenience and a wide range of healthcare products, including therapeutic vaccines. Additionally, they cater to diverse patient needs, making therapeutic vaccines more accessible to the masses.

Online pharmacies offer a convenient platform to purchase therapeutic vaccines remotely. They provide a wide selection, price comparisons, and home delivery, which are particularly advantageous for patients with mobility limitations or those seeking privacy.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America exhibits a clear dominance, accounting for the largest therapeutic vaccines market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share since the region has a well-developed healthcare infrastructure, comprising modern hospitals, research institutions, and pharmaceutical companies, which accelerates research, development, and commercialization of therapeutic vaccines. Additionally, North America is a global hub for medical research and innovation, housing renowned universities, research centers, and biotechnology firms. Apart from this, regulatory agencies in North America, such as the U.S. Food and Drug Administration (FDA) and Health Canada, maintain rigorous standards for drug and vaccine approvals. Moreover, North America has a well-established clinical trial ecosystem, which facilitates the efficient testing and validation of therapeutic vaccines. The availability of diverse patient populations and expert medical professionals expedites the trial process.

COMPETITIVE LANDSCAPE:

Companies are investing in research to identify novel antigens and develop innovative vaccine platforms, which include exploring cutting-edge technologies like mRNA-based vaccines, viral vectors, and personalized vaccine approaches. Additionally, many vaccine developers are conducting rigorous clinical trials to evaluate the safety and efficacy of their products. Furthermore, they are working closely with regulatory agencies to obtain approvals for their therapeutic vaccines. This involves compiling comprehensive data from clinical trials to demonstrate safety, efficacy, and manufacturing quality. Moreover, many leading companies are investing in infrastructure and technologies to ensure consistent and efficient vaccine production.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Agenus Inc.
  • Bavarian Nordic
  • CEL-SCI Corporation
  • Dendreon Pharmaceuticals LLC
  • Emergent BioSolutions
  • GeoVax
  • GSK plc
  • Merck & Co., Inc.
  • Novavax
  • Nykode Therapeutics ASA
  • Pfizer Inc.
  • Phio Pharmaceuticals
  • Sanofi S.A

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What was the size of the global therapeutic vaccines market in 2025?

2. What is the expected growth rate of the global therapeutic vaccines market during 2026-2034?

3. What are the key factors driving the global therapeutic vaccines market?

4. What has been the impact of COVID-19 on the global therapeutic vaccines market?

5. What is the breakup of the global therapeutic vaccines market based on the type?

6. What is the breakup of the global therapeutic vaccines market based on the disease type?

7. What is the breakup of the global therapeutic vaccines market based on the technology?

8. What are the key regions in the global therapeutic vaccines market?

9. Who are the key players/companies in the global therapeutic vaccines market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Therapeutic Vaccines Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Antigen Vaccines
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Dendritic Cell Vaccine
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 DNA Vaccine
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Tumor Cell Vaccines
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Disease Type

  • 7.1 Autoimmune Disease Vaccines
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Addiction Vaccine
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Neurological Disease Vaccine
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Infectious Disease Vaccine
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Technology

  • 8.1 Autologous Vaccines
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Allogeneic Vaccine
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Online Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Agenus Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Bavarian Nordic
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
    • 15.3.3 CEL-SCI Corporation
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Dendreon Pharmaceuticals LLC.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Emergent BioSolutions
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 GeoVax
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 GSK plc
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Merck & Co., Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Novavax
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Nykode Therapeutics ASA
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Pfizer Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Phio Pharmaceuticals
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 Sanofi S.A
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Therapeutic Vaccines Market: Major Drivers and Challenges
  • Figure 2: Global: Therapeutic Vaccines Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Therapeutic Vaccines Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Therapeutic Vaccines Market: Breakup by Type (in %), 2025
  • Figure 5: Global: Therapeutic Vaccines Market: Breakup by Disease Type (in %), 2025
  • Figure 6: Global: Therapeutic Vaccines Market: Breakup by Technology (in %), 2025
  • Figure 7: Global: Therapeutic Vaccines Market: Breakup by Distribution Channel (in %), 2025
  • Figure 8: Global: Therapeutic Vaccines Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Therapeutic Vaccines (Antigen Vaccines) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Therapeutic Vaccines (Antigen Vaccines) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Therapeutic Vaccines (Dendritic Cell Vaccine) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Therapeutic Vaccines (Dendritic Cell Vaccine) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Therapeutic Vaccines (DNA Vaccine) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Therapeutic Vaccines (DNA Vaccine) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Therapeutic Vaccines (Tumor Cell Vaccines) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Therapeutic Vaccines (Tumor Cell Vaccines) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Therapeutic Vaccines (Autoimmune Disease Vaccines) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Therapeutic Vaccines (Autoimmune Disease Vaccines) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Therapeutic Vaccines (Addiction Vaccine) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Therapeutic Vaccines (Addiction Vaccine) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Therapeutic Vaccines (Neurological Disease Vaccine) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Therapeutic Vaccines (Neurological Disease Vaccine) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Therapeutic Vaccines (Infectious Disease Vaccine) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Therapeutic Vaccines (Infectious Disease Vaccine) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Therapeutic Vaccines (Other Disease Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Therapeutic Vaccines (Other Disease Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Therapeutic Vaccines (Autologous Vaccines) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Therapeutic Vaccines (Autologous Vaccines) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Therapeutic Vaccines (Allogeneic Vaccine) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Therapeutic Vaccines (Allogeneic Vaccine) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Therapeutic Vaccines (Hospital Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Therapeutic Vaccines (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Global: Therapeutic Vaccines (Retail Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Global: Therapeutic Vaccines (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Global: Therapeutic Vaccines (Online Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Global: Therapeutic Vaccines (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: North America: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: North America: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: United States: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: United States: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Canada: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Canada: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Asia-Pacific: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Asia-Pacific: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: China: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: China: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Japan: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Japan: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: India: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: India: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: South Korea: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: South Korea: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Australia: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Australia: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Indonesia: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Indonesia: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Others: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Others: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Europe: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Europe: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Germany: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Germany: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: France: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: France: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: United Kingdom: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: United Kingdom: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Italy: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Italy: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Spain: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Spain: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Russia: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Russia: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Others: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Others: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Latin America: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Latin America: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Brazil: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Brazil: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: Mexico: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 80: Mexico: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Others: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 82: Others: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 83: Middle East and Africa: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 84: Middle East and Africa: Therapeutic Vaccines Market: Breakup by Country (in %), 2025
  • Figure 85: Middle East and Africa: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 86: Global: Therapeutic Vaccines Industry: SWOT Analysis
  • Figure 87: Global: Therapeutic Vaccines Industry: Value Chain Analysis
  • Figure 88: Global: Therapeutic Vaccines Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Therapeutic Vaccines Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Therapeutic Vaccines Market Forecast: Breakup by Type (in Million USD), 2026-2034
  • Table 3: Global: Therapeutic Vaccines Market Forecast: Breakup by Disease Type (in Million USD), 2026-2034
  • Table 4: Global: Therapeutic Vaccines Market Forecast: Breakup by Technology (in Million USD), 2026-2034
  • Table 5: Global: Therapeutic Vaccines Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 6: Global: Therapeutic Vaccines Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Therapeutic Vaccines Market: Competitive Structure
  • Table 8: Global: Therapeutic Vaccines Market: Key Players